Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации11394Conference ProceedingsThe Role of High-Sensitivity C-Reactive Protein in Predicting Cardiovascular Disease: International ExperienceEgorskaiaAnastasiia Timofeevnaegorskaya00@mail.ruhttps://orcid.org/0000-0002-1594-9572BorovkovaNatalia Yurievnaborovkov-nn@mail.ruhttps://orcid.org/0000-0001-7581-4138Privolzhsky Research Medical University0110202615S193950203202617032026Copyright © 2026, Egorskaia A.T., Borovkova N.Y.2026<p>There is growing evidence in the literature demonstrating a higher actual 10-year risk of death from cardiovascular (CV) outcomes compared to the risk predicted by existing, universally accepted CV risk assessment scales. High-sensitivity C-reactive protein (hsCRP) is considered to reclassify CV risk. The Aim. To examine international literature data on the prognostic role of hsCRP concentrations in the development of CV events. Materials and Methods. The search for sources was performed in the PubMed Advanced search builder in English using the keywords "high sensitivity C-reactive protein", "hsCRP", "cardiovascular", "risk", "risk factor", "odds ratio", and "healthy" in the title/abstract. Results. Large prognostic studies of the population of the United States of America, Great Britain, China, Japan, and African countries have shown an increased risk of coronary heart disease, myocardial infarction, the total number of CV events, and CV mortality with elevated hsCRP concentrations, including for patients with arterial hypertension and type 2 diabetes mellitus. However, data on the prediction of stroke, especially hemorrhagic stroke, is controversial. No association was found in South Asia research participants. Odds ratios and confidence intervals vary. An increased CV risk is noted in men. However, there is data refuting the predictive ability of hsCRP in the context of the development of CV diseases. It is suggested that it is necessary to identify a target population group in which hsCRP improves CV risk prediction. Conclusions. There is a large body of data in the international literature demonstrating the significant contribution of hsCRP to CV risk prediction. However, there is still no consensus on the independent role of hsCRP as a CV risk factor. Analysis of the Russian population is of interest.</p>hsCRPhigh-sensitivity C-reactive proteincardiovascular diseasescardiovascular riskprognosisodds ratioвчСРБвысокочувствительный С-реактивный белоксердечно-сосудистые заболеваниясердечно-сосудистый рискпрогнозированиеотношение шансов1.Olsen MH, Sehestedt T, Lyngbaek S, Hansen TW, Rasmussen S, Wachtell K, Torp-Pedersen C, Hildebrandt PR, Ibsen H. Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide--three new cardiovascular risk markers--do they improve risk prediction and influence treatment? Curr Vasc Pharmacol. 2010 Jan;8(1):134-9. doi: 10.2174/157016110790226633.2.Frary CE, Blicher MK, Olesen TB, Stidsen JV, Greve SV, Vishram-Nielsen JK, Rasmussen SL, Olsen MH, Pareek M. Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort. Eur J Prev Cardiol. 2020 Apr;27(6):570-578. doi: 10.1177/2047487319885457.3.Verma A, Lavie CJ, Milani RV. C-Reactive Protein: How Has JUPITER Impacted Clinical Practice? Ochsner J. 2009 Winter;9(4):204-10.4.Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009 Oct 6;151(7):483-95. doi: 10.7326/0003-4819-151-7-200910060-00009.5.Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009 Oct 6;151(7):483-95. doi: 10.7326/0003-4819-151-7-200910060-00009.6.Kurt B, Reugels M, Schneider KM, Spiesshoefer J, Milzi A, Gombert A, Fordyce CB, Wenzl FA, Pagidipati NJ, Rocha V, Fudim M, Sharma A, Lehrke M, Shimokawa H, Liuzzo G, Tokgozoglu L, Crea F, Lüscher TF, Libby P, Ridker PM, Marx N, Schneider CV, Kahles F. C-reactive protein and cardiovascular risk in the general population. Eur Heart J. 2025 Dec 11:ehaf937. doi: 10.1093/eurheartj/ehaf937.7.Ridker PM, Figtree GA, Moorthy MV, Mora S, Buring JE. C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the 'SMuRF-less but inflamed'. Eur Heart J. 2026 Jan 16;47(3):306-314. doi: 10.1093/eurheartj/ehaf658.8.Nordestgaard AT, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE, Ridker PM. High-sensitivity C-reactive protein, LDL cholesterol, lipoprotein(a) and 30-year risk of stroke in healthy women: a prospective, longitudinal cohort study. Lancet Neurol. 2025 Nov;24(11):920-930. doi: 10.1016/S1474-4422(25)00306-0.9.Hartley A, Rostamian S, Kaura A, Chrysostomou P, Welsh P, Ariti C, Sattar N, Sever P, Khamis R. The relationship of baseline high-sensitivity C-reactive protein with incident cardiovascular events and all-cause mortality over 20 years. EBioMedicine. 2025 Jul;117:105786. doi: 10.1016/j.ebiom.2025.105786.10.Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, Reeskamp LF, Stroes ESG, Hovingh GK, Boekholdt SM, Ridker PM. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. Eur Heart J. 2025 Oct 14;46(39):3875-3884. doi: 10.1093/eurheartj/ehaf209.11.Punithan A, Ghamarian E, Grothe D, MacLean M, Connelly K, Neal B, Weisman A, Cherney DZI, Billia F, Udell JA. FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial. JACC Adv. 2025 Dec;4(12 Pt 2):102276. doi: 10.1016/j.jacadv.2025.102276.12.Wang Y, Duan Y, Zhang Y, Li N, Hu Y, Gu L, Hou Y, Ma Y. Alcohol consumption, high-sensitivity C-reactive protein, and estimated glomerular filtration rate: tripartite predictors of 10-year cardiovascular risk progression in patients with type 2 diabetes mellitus after COVID-19. Front Endocrinol (Lausanne). 2025 Aug 26;16:1609144. doi: 10.3389/fendo.2025.1609144.13.Landman GW, Kleefstra N, Groenier KH, Bakker SJ, Groeneveld GH, Bilo HJ, van Hateren KJ. Inflammation biomarkers and mortality prediction in patients with type 2 diabetes (ZODIAC-27). Atherosclerosis. 2016 Jul;250:46-51. doi: 10.1016/j.atherosclerosis.2016.04.015.14.Siripuram C, Gunde AK, Hegde SV, Ghetia KS, Kandimalla R. Exploring Cardiovascular Health: The Role of Dyslipidemia and Inflammation. Cureus. 2025 Feb 10;17(2):e78818. doi: 10.7759/cureus.78818.15.Wang Y, Zhang X, Liang A, Niu Y, Chen D, Du Z, Wu W, Zhang F, Wu G, Fang Y, Shang X, Zhu Z, Hu Y, Chen X, Yu H, Hu L. High-sensitivity C-reactive protein and risk of retinal artery occlusion and ischaemic stroke: a cross-cohort study. Br J Ophthalmol. 2025 Aug 20;109(9):1081-1087. doi: 10.1136/bjo-2023-325044.16.Zuo Y, Chen S, Wu S, Wang A. Association between inflammation and cardiovascular disease in the absence of risk factors. Nutr Metab Cardiovasc Dis. 2026 Feb;36(2):104291. doi: 10.1016/j.numecd.2025.104291.17.Beverloo CYY, Annink ME, Kraaijenhof JM, Reeskamp LF, Galenkamp H, van den Born BH, Stroes ESG, Nurmohamed NS. High-sensitivity C-reactive protein and cardiovascular events in a multi-ethnic cohort: the HELIUS study. Eur J Prev Cardiol. 2025 Nov 19:zwaf740. doi: 10.1093/eurjpc/zwaf740.18.Dong Y, Wang X, Zhang L, Chen Z, Zheng C, Wang J, Kang Y, Shao L, Tian Y, Wang Z; China CVD study investigators. High-sensitivity C reactive protein and risk of cardiovascular disease in China-CVD study. J Epidemiol Community Health. 2019 Feb;73(2):188-192. doi: 10.1136/jech-2018-211433.19.Zheng L, Ye J, Liao X, Li J, Wang Q, Wang F. Frailty, high-sensitivity C-reactive protein and cardiovascular disease: a nationwide prospective cohort study. Aging Clin Exp Res. 2025 Feb 28;37(1):58. doi: 10.1007/s40520-025-02928-6.20.Iso H, Cui R, Date C, Kikuchi S, Tamakoshi A; JACC Study Group. C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study. Atherosclerosis. 2009 Nov;207(1):291-7. doi: 10.1016/j.atherosclerosis.2009.04.020.21.Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397.22.Clearfield, Michael B.. "C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease" Journal of Osteopathic Medicine, vol. 105, no. 9, 2005, pp. 409-416. https://doi.org/10.7556/jaoa.2005.105.9.40923.Bambs CE, Pollack I, Swanson J, Duan J, McKennan C, Kip K, Buysse D, Reis SE, Saeed A. Impact of life's essential eight and inflammatory markers on long-term cardiovascular disease risk and all-cause mortality: Insights from the Heart SCORE study. Heart Lung. 2026 Jan 13;77:102710. doi: 10.1016/j.hrtlng.2025.102710.24.Schmermund, Axel et al. Predictive ability of coronary artery calcium and CRP. The Lancet, Volume 378, Issue 9792, 641 - 64325.Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, O'Leary DH, Lima J, Blumenthal RS, Nasir K. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011 Aug 20;378(9792):684-92. doi: 10.1016/S0140-6736(11)60784-8. PMID: 21856482; PMCID: PMC3173039.26.Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG. Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol. 2010 May 11;55(19):2080-91. doi: 10.1016/j.jacc.2009.12.047. PMID: 20447530.27.Neumann JT, et al. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024 Jun 11;331(22):1898-1909. doi: 10.1001/jama.2024.5596.